Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric Chickenpox

  • Author: Kirsten A Bechtel, MD; Chief Editor: Russell W Steele, MD  more...
Updated: Apr 13, 2016


Varicella, commonly known in the United States as chickenpox, is caused by the varicella-zoster virus. The disease is generally regarded as a mild, self-limiting viral illness with occasional complications. Varicella is common and highly contagious and affects nearly all susceptible children before adolescence. Although most varicella infection confers life-long immunity, varicella clinical reinfections among healthy children have been described.[1] (See Pathophysiology and Etiology.)

Before vaccination for varicella became widespread in the United States, this disease affected approximately 4 million children per year, caused as many as 100 deaths in children annually, and was responsible for an estimated $400 million in medical costs and lost wages each year. Since the varicella vaccine was introduced for children aged 12-18 months in the United States in 1995 and booster vaccine given at age 4-5 years, disease incidence has substantially decreased. (See Epidemiology.)

Chickenpox is usually a benign disease in children, and almost all children recover uneventfully. (See Prognosis.) However, varicella is not totally benign even today. A significant number of varicella cases are associated with complications, among the most serious of which are varicella pneumonia and encephalitis.

Presenting symptoms may include a history of low-grade fever, abdominal pain, a history of rash, intense pruritus, headache, malaise, anorexia, cough and coryza, and sore throat. Rash and fever are the typical findings during physical examination in pediatric patients with varicella. An ill appearance should raise concern for pulmonary or neurologic complications or serious bacterial superinfection. (See Clinical Presentation.)

Adolescents, adults, and pregnant patients are at increased risk for severe disease and are often treated with antivirals. Other groups that require specific treatment are children who are immunocompromised, those who are otherwise at risk for severe disease, and those who already have severe disease. Other treatments include supportive measures, administration of varicella zoster immune globulin (VZIG), and management of secondary bacterial infection. (See Treatment and Management.)

Go to Chickenpox for complete nonpediatric information on this topic.



The causative organism, varicella-zoster virus, is a member of the human herpesvirus subfamily Alphaherpesvirinae and, like all herpes viruses, is a DNA virus. The virus enters through the respiratory system (conjunctival or upper respiratory mucosa) and colonizes the upper respiratory tract. Viral replication takes place in regional lymph nodes over the next 2-4 days; 4-6 days later, a primary viremia spreads the virus to reticuloendothelial cells in the spleen, liver, and elsewhere.

After a week, a secondary viremia disseminates the virus to the viscera and skin, eliciting the typical skin lesions (see the images below).[2] This viremia also spreads the virus to respiratory sites and is responsible for the contagion of varicella before the appearance of the rash. Infection of the central nervous system (CNS) or liver also occurs at this time, as may encephalitis, hepatitis, or pneumonia.

The pleomorphic rash characteristic of varicella. The pleomorphic rash characteristic of varicella. Papules, vesicles, and pustules are concurrently present.
Papulovesicular lesions on arm in varying stages o Papulovesicular lesions on arm in varying stages of healing in this infant with varicella. Photograph courtesy of Susan Feigelman, MD.

The usual incubation period is 10-21 days. The patient is contagious from 1-2 days before the appearance of rash until the lesions crust over, usually 5-6 days after the rash first appears.

Varicella is associated with humoral and cell-mediated immune responses. These responses induce long-lasting immunity. Repeat subclinical infection can occur in these persons, but second attacks of chickenpox are extremely rare in immunocompetent persons. Reexposure and subclinical infections may serve to boost the immunity acquired after an episode of chickenpox. This may change in the post vaccine era.




Varicella is caused by the varicella-zoster virus. The infectious particles are cell-free virus particles derived from skin lesions or the respiratory tract. Transmission occurs mainly through respiratory droplets that contain the virus, making the disease highly contagious even before the rash appears. Direct person-to-person contact with lesions also spreads the virus. Papules and vesicles, but not the crusts, have high populations of the virus. In addition, maternal varicella with viremia can transplacentally spread to the fetus. This leads to neonatal varicella.

Risk factors for severe varicella

Risk factors for severe varicella in neonates are as follows:

  • The first month of life: A neonate’s first month of life is a susceptible period for severe varicella, especially if the mother is seronegative.
  • Early delivery: Delivery before 28 weeks’ gestation also renders a baby susceptible because transplacental transfer of immunoglobulin G (IgG) antibodies occurs after this time.

Risk factors for severe varicella in adolescents and adults are as follows:

  • Steroid therapy: High doses (ie, doses equivalent to 1-2 mg/kg/d of prednisolone) for 2 weeks or more are definite risk factors for severe disease. Even short-term therapy at these doses immediately preceding or during the incubation period of varicella can cause severe or fatal varicella. [3]
  • Malignancy: All children with cancer have an increased risk for severe varicella. The risk is highest for children with leukemia. Almost 30% of patients who are immunocompromised and who have leukemia have visceral dissemination of varicella; 7% may die.
  • Immunocompromised state (eg, malignancy, antimalignancy drugs, human immunodeficiency virus [ HIV], other congenital or acquired immunodeficient conditions): Defects of cellular but not humoral immunodeficiency are believed to render a person susceptible to severe varicella.
  • Pregnancy: Pregnant women have high risk of severe varicella, especially pneumonia.


United States statistics

Before varicella vaccine use became widespread, 4 million cases of chickenpox were reported annually. National seroprevalence data for 1988-1994 indicated that 95.5% of adults aged 20-29 years, 98.9% of adults aged 30-39 years, and more than 99.6% of adults older than 40 years were immune to varicella.[4] The disease was responsible for 11,000 hospitalizations each year and approximately 50-100 deaths.

The adoption of universal vaccination against varicella in 1995 reduced the incidence of varicella, as well as the associated morbidity and mortality rates.[5, 6, 7, 8] By 2000, vaccination coverage among children 19-35 months in 3 communities in Texas, California, and Pennsylvania had reached 74-84%, and reported total varicella cases had declined 71-84%. Most of the decline occurred among children aged 12 months to 4 years; however, incidence declined in all age groups, including infants and adults.[9]

Currently, fewer than 10 deaths occur per year, most of them in unimmunized people. Although vaccination coverage has exceeded 80% over the past few years, outbreaks of breakthrough varicella still occur in schools and daycare centers.[10, 11, 12]

Children with varicella expose adult contacts in households,[13] schools, and daycare centers to the risk of severe, even fatal, disease. Household transmission rates are 80-90%. Second cases within the household are often more severe. School or daycare center contact is associated with lower but still significant transmission rates. Children who are susceptible rarely acquire the disease by contact with adults with zoster. Maximum transmission occurs during late winter and spring.

International statistics

Varicella affects nearly all children worldwide who do not have immunity. Annual incidence is estimated at 80-90 million cases. Most developing countries have low immunization rates because of the cost involved, and varicella disease is a risk for travelers to such countries.

A survey of 1473 cases in Japan demonstrated that 81.4% involved children younger than 6 years.[14] In Japan, the annual prevalence peaked between March and May, with subsequent lower prevalence between August and October.

The epidemiology of varicella differs between countries with temperate climates and those with tropical climates. In most countries with temperate climates, more than 90% of persons are infected by adolescence but in countries with tropical climates, a higher proportion of infections are acquired at older ages, which results in higher susceptibility among adults.

Age distribution for varicella

The maximum incidence of varicella in unvaccinated populations is in children aged 1-6 years. Persons older than 14 years account for 10% of varicella cases. In the United States, the peak age is now 9-11 years.[5]

In tropical climates, varicella is more common in older children. Most cases in Japan were in children younger than 6 years. Approximately 9.6% of cases involved children younger than 1 year, and almost one third of these were infants younger than 5 months.

Varicella does not have a racial predilection or a sex predilection.



Otherwise healthy children with varicella have excellent prognoses. In otherwise healthy children aged 1-14 years, the mortality rate is estimated at 2 deaths per 100,000 cases. The case-fatality rate in the general population is 6.7 cases per 100,000 population. Children with immunocompromised states, however, are at risk for severe disease and death. The mortality rate in children who are immunocompromised is much higher than that in otherwise healthy children. Among children with leukemia, the mortality rate of varicella is 7%.

One study suggested that nearly 1:50 varicella cases are associated with complications. Among the most serious complications are varicella pneumonia and encephalitis; both are associated with a high mortality rate. Before universal vaccination, most varicella-related deaths in the United States were from associated encephalitis, pneumonia, secondary bacterial infection, and Reye syndrome. (See Complications.) In addition, significant concerns have been raised about the association of varicella with severe invasive group A streptococcal disease.[15]

The disease can be serious in neonates, depending on the timing of infection in the mother. Varicella during pregnancy can cause various adverse outcomes for mother and infant, depending on the stage of pregnancy. Neonatal varicella mortality rates can reach 30%.


Patient Education

Families of children with chickenpox should be instructed to bathe the child regularly to reduce itching and prevent secondary infection. To prevent scratching, which can lead to secondary infection and scarring, the child’s fingernails should be kept short, mittens or socks may be worn on the hands at night, and medication for itching can be given as needed. Aspirin-containing medications should not be used.

Children with chickenpox should avoid nonimmune pregnant women, unimmunized young infants, and others with immunodeficiencies or who are taking prednisone long term. Children with chickenpox may not return to school or day care until all lesions are crusted over.

Parents should take children to the hospital if the following symptoms occur:

  • Unusual redness, swelling, or pain over an area of the rash
  • Refusal to drink fluids
  • Signs of dehydration, such as scanty and yellow-colored urine, increasing drowsiness, dry mouth and lips, excessive thirst, or lethargy
  • Confusion, irritability, drowsiness, or difficulty waking
  • Inability to walk or unusual weakness
  • Complaints of severe headache, stiff neck, and/or back pain
  • Frequent vomiting
  • Difficulty breathing, chest pain, wheezing, fast breathing, or severe cough
  • Fever persisting more than 4 days or fever returns after defervescence
  • A more sickly appearance than when last seen by the doctor

For patient education resources, see the Bacterial and Viral Infections Center, as well as Chickenpox and Skin Rashes in Children.

Contributor Information and Disclosures

Kirsten A Bechtel, MD Associate Professor of Pediatrics, Section of Pediatric Emergency Medicine, Yale University School of Medicine; Co-Director, Injury Free Coalition for Kids, Yale-New Haven Children's Hospital

Kirsten A Bechtel, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.


Parang N Mehta, MD Consulting Staff, Department of Pediatrics, Mehta Hospital, India

Parang N Mehta, MD is a member of the following medical societies: Indian Medical Association, Indian Academy of Pediatrics

Disclosure: Nothing to disclose.

Richard Lichenstein, MD Professor, Pediatric Emergency Department, University of Maryland School of Medicine

Richard Lichenstein, MD is a member of the following medical societies: American Medical Association, American Academy of Pediatrics

Disclosure: Nothing to disclose.

Archana Chatterjee, MD, PhD Professor and Chair, Department of Pediatrics, Senior Associate Dean for Faculty Development, Sanford School of Medicine, The University of South Dakota

Archana Chatterjee, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, International Society for Infectious Diseases, Pediatric Infectious Diseases Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

Leonard R Krilov, MD Chief of Pediatric Infectious Diseases and International Adoption, Vice Chair, Department of Pediatrics, Winthrop University Hospital; Professor of Pediatrics, Stony Brook University School of Medicine

Leonard R Krilov, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Society for Pediatric Research

Disclosure: Nothing to disclose.


Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

  1. Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, et al. Second varicella infections: are they more common than previously thought?. Pediatrics. 2002 Jun. 109(6):1068-73. [Medline].

  2. Rockley PF, Tyring SK. Pathophysiology and clinical manifestations of varicella zoster virus infections. Int J Dermatol. 1994 Apr. 33(4):227-32. [Medline].

  3. Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993 Aug. 92(2):223-8. [Medline].

  4. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics. 2004 Sep. 114(3):786-92. [Medline].

  5. [Guideline] American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics. 2007. 120:221-231. [Medline]. [Full Text].

  6. Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA. 2005 Aug 17. 294(7):797-802. [Medline]. [Full Text].

  7. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005 Feb 3. 352(5):450-8. [Medline].

  8. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002 Feb 6. 287(5):606-11. [Medline].

  9. Shah SS, Wood SM, Luan X, Ratner AJ. Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr Infect Dis J. 2010 Mar. 29(3):199-204. [Medline]. [Full Text].

  10. National, state, and local area vaccination coverage among children aged 19-35 months--United States, 2006. MMWR Morb Mortal Wkly Rep. 2007 Aug 31. 56(34):880-5. [Medline].

  11. Buchholz U, Moolenaar R, Peterson C, Mascola L. Varicella outbreaks after vaccine licensure: should they make you chicken?. Pediatrics. 1999 Sep. 104(3 Pt 1):561-3. [Medline]. [Full Text].

  12. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002 Dec 12. 347(24):1909-15. [Medline]. [Full Text].

  13. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA. 2004 Aug 11. 292(6):704-8. [Medline].

  14. Ozaki T, Nagai H, Kimura T, Ichikawa T, Suzuki S, Kito H, et al. The age distribution of neutralizing antibodies against varicella-zoster virus in healthy individuals. Biken J. 1980 Mar. 23(1):9-14. [Medline].

  15. Kouwabunpat D, Hoffman J, Adler R. Varicella complicated by group A streptococcal sepsis and osteonecrosis. Pediatrics. 1999 Oct. 104(4 Pt 1):967-9. [Medline]. [Full Text].

  16. Perella D, Fiks AG, Jumaan A, Robinson D, Gargiullo P, Pletcher J, et al. Validity of reported varicella history as a marker for varicella zoster virus immunity among unvaccinated children, adolescents, and young adults in the post-vaccine licensure era. Pediatrics. 2009 May. 123(5):e820-8. [Medline].

  17. Cowan MR, Primm PA, Scott SM, Abramo TJ, Wiebe RA. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med. 1994 Apr. 23(4):818-22. [Medline].

  18. Doctor A, Harper MB, Fleisher GR. Group A beta-hemolytic streptococcal bacteremia: historical overview, changing incidence, and recent association with varicella. Pediatrics. 1995 Sep. 96(3 Pt 1):428-33. [Medline].

  19. Lesko SM, O'Brien KL, Schwartz B, Vezina R, Mitchell AA. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics. 2001 May. 107(5):1108-15. [Medline].

  20. Tappeiner C, Aebi C, Garweg JG. Retinitis and optic neuritis in a child with chickenpox: case report and review of literature. Pediatr Infect Dis J. 2010 Dec. 29(12):1150-2. [Medline].

  21. Matsukura H, Murakami M, Sakaki H, Mitani T, Shimura S. Varicella glomerulonephritis preceding the cutaneous lesions. Clin Nephrol. 2009 Aug. 72(2):161-2. [Medline].

  22. Chickenpox in Pregnancy. RCOG Green-top Guideline No. 13. Available at Accessed: May 11, 2015.

  23. Barclay L. Guidelines Revised on Chicken Pox in Pregnancy. Medscape Medical News. Available at Accessed: May 11, 2015.

  24. Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med. 1994 Mar 31. 330(13):901-5. [Medline]. [Full Text].

  25. Derrick CW Jr, Lord L. In utero varicella-zoster infections. South Med J. 1998 Nov. 91(11):1064-6. [Medline].

  26. American Academy of Pediatrics Committee on Infectious Diseases: The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics. 1993 Mar. 91(3):674-6. [Medline].

  27. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of VariZIG – United States, 2013. Available at Accessed: July 23, 2013.

  28. [Guideline] Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008 Sep. 122(3):e744-51. [Medline]. [Full Text].

  29. Pinquier D, Gagneur A, Balu L, et al. Prevalence of anti-varicella-zoster virus antibodies in French infants under 15 months of age. Clin Vaccine Immunol. 2009 Apr. 16(4):484-7. [Medline]. [Full Text].

  30. [Guideline] Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008 Mar 14. 57(10):258-60. [Medline].

  31. [Guideline] Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Jun 22. 56:1-40. [Medline].

  32. Lee LE, Ho H, Lorber E, et al. Vaccine-era varicella epidemiology and vaccine effectiveness in a public elementary school population, 2002-2007. Pediatrics. 2008 Jun. 121(6):e1548-54. [Medline]. [Full Text].

  33. Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics. 2003 Aug. 112(2):e98-103. [Medline]. [Full Text].

  34. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007 Mar 15. 356(11):1121-9. [Medline].

  35. Arbeter AM, Granowetter L, Starr SE, et al. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics. 1990 Mar. 85(3):338-44. [Medline].

  36. Quian R J, Protasio P A, Dall'orso V P, et al. [Varicella outbreak in a village in Uruguay]. Rev Chilena Infectol. 2010 Feb. 27(1):47-51. [Medline]. [Full Text].

  37. Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C. Postexposure effectiveness of varicella vaccine. Pediatrics. 2000 Jan. 105(1 Pt 1):84-8. [Medline].

  38. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010 Jul. 126(1):e1-8. [Medline].

  39. Hviid A. Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. J Pediatr. 2011 Jan. 158(1):170. [Medline].

  40. [Guideline] Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 May 7. 59:1-12. [Medline].

  41. American Academy of Pediatrics Committee on Infectious Diseases. Policy Statement--Prevention of Varicella: Update of Recommendations for Use of Quadrivalent and Monovalent Varicella Vaccines in Children. Pediatrics. 2011 Aug 28. [Medline].

  42. Marin M, Marti M, Kambhampati A, Jeram SM, Seward JF. Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics. 2016 Mar. 137 (3):1-10. [Medline].

The pleomorphic rash characteristic of varicella. Papules, vesicles, and pustules are concurrently present.
Papulovesicular lesions on arm in varying stages of healing in this infant with varicella. Photograph courtesy of Susan Feigelman, MD.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.